Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;356(5):e2200421.
doi: 10.1002/ardp.202200421. Epub 2023 Jan 8.

Pyrazole scaffold-based derivatives: A glimpse of α-glucosidase inhibitory activity, SAR, and route of synthesis

Affiliations
Review

Pyrazole scaffold-based derivatives: A glimpse of α-glucosidase inhibitory activity, SAR, and route of synthesis

Jannat Ul Firdaus et al. Arch Pharm (Weinheim). 2023 May.

Abstract

The α-glucosidase is a validated target to develop drugs for treating type 2 diabetes mellitus. The existing α-glucosidase inhibitors have certain shortcomings related to side effects and route of synthesis. Accordingly, it is inevitable to develop new chemical templates as α-glucosidase inhibitors. Pyrazole derivatives have a special place in medicinal chemistry because of various biological activities. Recently, pyrazole-based heterocyclic compounds have emerged as a promising scaffold to develop α-glucosidase inhibitors. This study focuses on the recently reported pyrazole-based α-glucosidase inhibitors, including their biological activity (in vivo, in vitro, and in silico), structure-activity relationship, and ways of synthesis. The literature revealed the development of several promising pyrazole-based α-glucosidase inhibitors and new synthetic routes for their preparation. The encouraging α-glucosidase inhibitory results of the pyrazole-based heterocyclic compounds make them an attractive target for further research. The authors also foresee the arrival of the pyrazole-based α-glucosidase inhibitors in clinical practice.

Keywords: biological activity; docking study; pyrazole; structure-activity relationship; α-glucosidase inhibitors.

PubMed Disclaimer

References

REFERENCES

    1. U. Galicia-Garcia, A. Benito-Vicente, S. Jebari, A. Larrea-Sebal, H. Siddiqi, K. B. Uribe, H. Ostolaza, C. Martín, Int. J. Mol. Sci. 2020, 21(17), 6275. https://doi.org/10.3390/ijms21176275
    1. A. Manaithiya, O. Alam, V. Sharma, M. Javed Naim, S. Mittal, I. A. Khan, Bioorg. Chem. 2021, 113, 104998. https://doi.org/10.1016/j.bioorg.2021.104998
    1. R. Kaur, L. Dahiya, M. Kumar, Eur. J. Med. Chem. 2017, 141, 473. https://doi.org/10.1016/j.ejmech.2017.09.029
    1. International Diabetes Federation. IDF Diabetes Atlas, Brussels, Belgium 2021. https://www.diabetesatlas.org
    1. P. Saeedi, I. Petersohn, P. Salpea, B. Malanda, S. Karuranga, N. Unwin, S. Colagiuri, L. Guariguata, A. A. Motala, K. Ogurtsova, J. E. Shaw, D. Bright, R. Williams, Diabetes Res. Clin. Pract. 2019, 157, 107843. https://www.elsevier.com/about/our-business/policies/article-withdrawal

MeSH terms

LinkOut - more resources